Biological Markers to Identify Early Sepsis and Acute Lung Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-09-30

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There are no clear markers to identify sepsis and acute lung injury at early stage in clinical settings which would result in improved survival of the patients. In collaboration with the research team led by Dr. Zhang at St. Michael's Hospital, Toronto, we have initiated a pilot study looking for biological markers to detect severe sepsis and ARDS. We have found that human neutrophils peptides (a-defensins), certain coagulation variables and cytokine levels are very sensitive markers to differentiate severe sepsis, ARDS from cardiovascular diseases in ICU patients. These findings may provide valuable information for therapeutic guideline in clinical practice. The present study will focus on testing 'biological markers' to identify patients with sepsis and acute lung injury. We will examine the roles of three components of markers including inflammation, neutrophil activation and coagulation. We are hoping that this proposed translational research will help develop novel therapeutic strategy in sepsis and acute lung injury patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Alpha-1-acid Glycoprotein as a Biomarker of Developmental Diagnosing and Monitoring Effectiveness in Sepsis

NCT01838525

Systemic Inflammatory Response Syndrome Sepsis

UNKNOWN

Biomarkers in Infection

NCT02545478

Sepsis Infection Inflammation

RECRUITING

Mechanisms of Precise Immune Cell Phenotyping and Prognostic Prediction in Severe Infection

NCT07332793

Sepsis

NOT_YET_RECRUITING

Sepsis-damaged Organs-double-markers Identification of Organ Failure Using Fluorescent Nanoparticle Tracking Analysis

NCT03222986

Sepsis With Multiple Organ Dysfunction (MOD)

COMPLETED

BIomarkers to Predict the Outcomes of Sepsis

NCT05842980

Sepsis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Acute Lung Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meet diagnostic criteria of ≧2 SIRS or acute lung injury.
* Get agreement of patient's attending physician and inform consent form patient or family.

Exclusion Criteria

* Use Antibiotics over 24 hrs（only SIRS group）.
* Active bleeding.
* Pregnancy.
* Active Cancer (refer to malignancy which is recently diagnosed, under treatment, or relapsed)
* VS or Subject or Family refuse

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes